BNTX Dec 2025 85.000 call
| Previous close | 39.98 |
| Open | N/A |
| Bid | 43.20 |
| Ask | 48.80 |
| Strike | 85.00 |
| Expiry date | 2025-12-19 |
| Day's range | 39.98 - 39.98 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
ZacksBioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?
On BioNTech's (BNTX) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its pipeline development now that the pandemic is over.
- Reuters
UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
ReutersGlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
(Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
